Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trial aims to solve long COVID chest pain mystery

NCT ID NCT07559994

Diagnosis Sponsor: Fundacion Investigacion Interhospitalaria Cardiovascular Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people with Long COVID who have new chest pain but no blocked arteries. It tests whether a special heart function test can guide treatment to improve symptoms and quality of life. 108 participants will be randomly assigned to either treatment guided by the test or standard care, and their progress will be tracked for 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
coronary functional test (diagnostic procedure)
What this could lead to
If successful, this could lead to a better way to diagnose and treat chest pain in Long COVID patients, improving their symptoms and quality of life.
What could go wrong
This is a small, early-stage trial with only 108 participants. The benefits of tailored treatment may not be significantly better than standard care, and results may not apply to all Long COVID patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- All patients with the history of SARS-CoV-2 infection, either with acute infection confirmed by PCR or antigen testing, or with past infection demonstrated by serological testing, with symptoms suggestive of LCS such as post exertional malaise, persistent fatigue, difficulty concentrating or shortness of breath who present with typical angina or angina equivalent chest pain starting after SARS-CoV2 infection Exclusion Criteria: * Previously been diagnosed with coronary artery disease * Severe left ventricular systolic dysfunction (LVEF) \< 30% * Any moderate to severe concomitant structural heart disease (e.g. moderate to severe valvular heart abnormalities, severe left ventricular hypertrophy) * Severely reduced renal function (glomerular filtration rate \< 30 ml/min/1.73m2) * Contraindications to the administration of Adenosine or Acetylcholine * A life expectancy of less than 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina (stable) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina, Stable Chest Pain coronary microvascular disorder intermediate coronary syndrome long COVID-19 nonobstructive coronary artery disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina (stable) Chronic coronary syndrome Inoca (ischemia with non obstructive coronary artery disease) Long COVID Long COVID-19 syndrome

Contacts and locations

Locations

  • Hospital Clinico San Carlos

    Madrid, Madrid, 28005, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.